Page 310 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 310
Chapter 12
Table 1. Patient characteristics
Patient characteristics of patients included in the primary analysis of this GWAS (N=599) and patients included in the Alpe DPD study (N=1,103). Data are N(%) or median(IQR). P-values comparing patients from the primary analysis to the Alpe DPD study patients. We used a nonparametric test for independent samples to compare medians of age, BSA, and number of treatment cycles; and a χ2 test for gender, ethnic origin, tumour type, treatment regimen and WHO performance status.
Characteristic
Gender
Male Female
Age in years [IQR] Ethnic origin
White Black Asian
Othera
Tumour type
Non-metastatic colorectal cancer Metastatic colorectal cancer Breast cancer
Gastric cancer Otherb
Type of treatment regimen
Capecitabine monotherapy (±bevacizumab) Capecitabine + radiotherapy (±mitomycin) Capecitabine + oxaliplatin (±bevacizumab) Capecitabine + other anticancer drugs Fluorouracil monotherapy Fluorouracil + radiotherapy (±mitomycin) Fluorouracil + oxaliplatin + folinic acid (±bevacizumab) Fluorouracil + other anticancer drugs
BSA [IQR]
WHO performance status
0 1 2
Not specifiedc
Number of treatment cycles [IQR] DPYD status
Wild-type c.1236G>A heterozygous c.2846A>T heterozygous DPYD*2A heterozygous DPYD*13 heterozygous
GWAS cohort (N=599)
319 (53.3%) 280 (46.7%)
64 [57─71]
573 (95.7%) 14 (2.3%)
9 (1.5%)
3 (<1%)
265 (44.2%) 114 (19%) 75 (12.5%) 32 (5.3%) 113 (18.9%)
102 (17%) 172 (28.7%) 179 (29.9%) 41 (6.8%)
-
43 (7.2%) 18 (3%)
44 (7.3%)
1.9 [1.8─2.1]
317 (52.9%) 241 (40.2%) 21 (3.5%)
-
3 [1-7]
599 (100%)
Alpe DPD study (N=1,103)
593 (53.8%) 510 (46.2%)
64 [56─71]
1048 (95%) 19 (1.7%) 24 (2.2%) 12 (1.1%)
472 (42.8%) 232 (21%) 141 (12.8%) 63 (5.7%) 195 (17.7%)
205 (18.6%) 264 (23.9%) 374 (33.9%) 72 (6.5%)
2 (<1%) 63 (5.7%) 43 (3.9%)
80 (7.3%)
1.9 [1.8─2.1]
554 (50.2%) 448 (40.6%) 42 (3.8%) 59 (5.3%)
3 [1-8]
1018 (92.3%) 51 (4.6%)
17 (1.5%)
16 (1.5%)
1 (<1%)
P-value
0.841
0.454
0.362
0.991
0.234
0.503
0.257
0.010
NA
308
